MARGARET SPITZ to Biomarkers, Tumor
This is a "connection" page, showing publications MARGARET SPITZ has written about Biomarkers, Tumor.
Connection Strength
1.254
-
Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer. J Thorac Oncol. 2016 Jan; 11(1):52-61.
Score: 0.270
-
Role of selected genetic variants in lung cancer risk in African Americans. J Thorac Oncol. 2013 Apr; 8(4):391-7.
Score: 0.223
-
Re: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2009 Dec 16; 101(24):1731-2; author reply 1732.
Score: 0.178
-
Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl. 1996; 25:80-4.
Score: 0.068
-
Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer. Genet Epidemiol. 2015 Mar; 39(3):197-206.
Score: 0.063
-
A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev. 2014 Sep; 23(9):1729-51.
Score: 0.061
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.057
-
Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2):251-60.
Score: 0.055
-
Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res. 2010 Aug 01; 16(15):3976-87.
Score: 0.046
-
Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1111-9.
Score: 0.040
-
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
Score: 0.035
-
Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Cancer. 2005 Jul 01; 104(1):30-5.
Score: 0.033
-
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11):1413-8.
Score: 0.027
-
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999 Jan 20; 91(2):151-6.
Score: 0.021
-
Genetic susceptibility to cancer. Cancer. 1993 Aug 01; 72(3 Suppl):991-5.
Score: 0.014
-
Activating enhancer-binding protein-2? nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep; 92(3):1044-50.
Score: 0.013
-
Differential induction in telomerase activity among bladder cancer patients and controls on gamma-radiation. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16(3):606-9.
Score: 0.009
-
Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5720-5.
Score: 0.009
-
Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1935-40.
Score: 0.009
-
Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer. 2003 Oct 20; 107(1):84-8.
Score: 0.007
-
Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. Cancer Detect Prev. 2002; 26(6):411-8.
Score: 0.006
-
Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst. 1997 Feb 05; 89(3):199-211.
Score: 0.005
-
Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer. 1994 Nov 01; 74(9 Suppl):2719-25.
Score: 0.004
-
Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst. 1990 Nov 21; 82(22):1773-5.
Score: 0.003